Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion

Novel adjuvant strategies are needed to optimize outcomes after complete surgical resection in patients with early-stage non-small-cell lung cancer (NSCLC). The adjuvant treatment of ROS Proto-Oncogene 1 (ROS1) fusion-positive resected NSCLC is challenging because there is no curative confirmed rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, An-guo, Chen, Dong-sheng, Li, Si, Zhao, Le-le, Xiao, Ming-zhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921990/
https://www.ncbi.nlm.nih.gov/pubmed/35299735
http://dx.doi.org/10.3389/fonc.2022.837219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921990/
https://www.ncbi.nlm.nih.gov/pubmed/35299735
http://dx.doi.org/10.3389/fonc.2022.837219

Ejemplares similares